

# LUPIN LIMITED

## SAFETY DATA SHEET

### Section 1: Identification

#### Section 1, Identification

<b>Material</b>	<b>Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets</b>
<b>Manufacturer</b>	<b>Lupin Limited</b> Pithampur (M.P.) – 454 775 INDIA.
<b>Distributor</b>	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

### Section 2: Hazard(s) Identification

#### Section 2, Hazard(s) identification

<b>Fire and Explosion</b>	Expected to be non-combustible.
<b>Health</b>	<p>Do not prescribe drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets to women who are known to have the following:</p> <ul style="list-style-type: none"><li>• Renal impairment</li><li>• Adrenal insufficiency</li><li>• A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<ul style="list-style-type: none"><li>○ Smoke, if over age 35</li><li>○ Have deep vein thrombosis or pulmonary embolism, now or in the past</li><li>○ Have cerebrovascular disease</li><li>○ Have coronary artery disease</li><li>○ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)</li><li>○ Have inherited or acquired hypercoagulopathies</li><li>○ Have uncontrolled hypertension</li><li>○ Have diabetes mellitus with vascular disease</li><li>○ Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35</li></ul></li><li>• Undiagnosed abnormal uterine bleeding</li><li>• Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past</li><li>• Liver tumors, benign or malignant, or liver disease</li><li>• Pregnancy, because there is no reason to use COCs during pregnancy</li><li>• Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations.</li></ul>

**Environment**

No information is available about the potential of this product to produce adverse environmental effects.

## Section 3: Composition/Information on Ingredients

**Section 3, Composition/information on ingredients**

<b>Ingredients</b>	<b>CAS</b>
Drospirenone USP	67392-87-4
Ethinyl Estradiol USP	57-63-6
Levomefolate Calcium	151533-22-1

## Section 4: First-Aid Measures

**Section 4, First-aid measures**

<b>Ingestion</b>	If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.
<b>Inhalation</b>	Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.
<b>Skin Contact</b>	Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.
<b>Eye Contact</b>	Flush eyes with plenty of water. Get medical attention.

**NOTES TO HEALTH PROFESSIONALS**

<b>Medical Treatment</b>	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.
--------------------------	---

<b>OVERDOSAGE</b>	<p>There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</p> <p>DRSP is a spironolactone analogue which has anti-mineralocorticoid properties. Serum concentration of potassium and sodium, and evidence of metabolic acidosis, should be monitored in cases of overdose.</p> <p>Levomefolate calcium doses of 17 mg/day (37-fold higher than the levomefolate calcium dose of drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets) were well tolerated after long-term treatment up to 12 weeks.</p>
-------------------	---

## Section 5: Fire-Fighting Measures

### Section 5, Fire-fighting measures

<b>Fire and Explosion Hazards</b>	Assume that this product is capable of sustaining combustion.
<b>Extinguishing Media</b>	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
<b>Special Firefighting Procedures</b>	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
<b>Hazardous Combustion Products</b>	Hazardous combustion or decomposition products are expected when the product is exposed to fire.

## Section 6: Accidental Release Measures

### Section 6, Accidental release measures

<b>Personal Precautions</b>	Wear protective clothing and equipment consistent with the degree of hazard.
<b>Environmental Precautions</b>	For large spills, take precautions to prevent entry into waterways sewers, or surface drainage systems.
<b>Clean-up Methods</b>	Collect and place it in a suitable, properly labeled container for recovery or disposal.

## Section 7: Handling and Storage

### Section 7, Handling and storage

<b>Handling</b>	No special control measures required for the normal handling of this product.  Normal room ventilation is expected to be adequate for routine handling of this product.
<b>Storage</b>	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

## Section 8: Exposure Controls/Personal Protection

### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

## Section 9: Physical and Chemical Properties

### Section 9, Physical and chemical properties

#### Physical Form

Drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets are available in 28 tablets wallet containing 28 tablets packed in a pouch (NDC 68180-894-11). Such three pouches are packaged in a carton (NDC 68180-894-13).

Each Wallet contains 28 film-coated tablets in the following order:

- 24 pink, round shaped, biconvex film-coated tablets debossed with "LU" on one side and "J61" on other side each containing 3 mg drospirenone, 0.02 mg ethinyl estradiol and 0.451 mg levomefolate calcium.
- 4 light orange, round shaped, biconvex film-coated tablets debossed with "LU" on one side and "J62" on other side each containing 0.451 mg levomefolate calcium.

## Section 10: Stability and Reactivity

### Section 10, Stability and reactivity

Stable under recommended storage conditions.

## Section 11: Toxicological Information

### Section 11, Toxicological information

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 24 month oral carcinogenicity study in mice dosed with 10 mg/kg/day DRSP alone or 1 + 0.01, 3 + 0.03 and 10 + 0.1 mg/kg/day of DRSP and EE, 0.1 to 2 times the exposure (AUC of DRSP) of women taking a contraceptive dose, there was an increase in carcinomas of the harderian gland in the group that received the high dose of DRSP alone. In a similar study in rats given 10 mg/kg/day DRSP alone or 0.3 + 0.003, 3 + 0.03 and 10 + 0.1 mg/kg/day DRSP and EE, 0.8 to 10 times the exposure of women taking a contraceptive dose, there was an increased incidence of benign and total (benign and malignant) adrenal gland pheochromocytomas in the group receiving the high dose of DRSP. Mutagenesis studies for DRSP were conducted *in vivo* and *in vitro* and no evidence of mutagenic activity was observed.

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of levomefolate. Mutagenesis studies for levomefolate were conducted *in vitro* and *in vivo* and no evidence of mutagenic activity was observed.

## Section 12: Ecological Information

### Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

### Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## Section 14: Transport Information

### Section 14: Transport Information

#### IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

#### IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

#### DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

## Section 15: Regulatory Information

### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## Section 16: Other Information

### Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.